Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia (Q33185518)

23 July 2017

Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia (English)

1 reference

23 July 2017

0 references

1 reference

Daniel E Casey

1

1 reference

23 July 2017

David G Daniel

2

1 reference

23 July 2017

Adel A Wassef

3

1 reference

23 July 2017

Katherine A Tracy

4

1 reference

23 July 2017

Patricia Wozniak

5

1 reference

23 July 2017

Kenneth W Sommerville

6

1 reference

23 July 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

23 July 2017

Neuropsychopharmacology

1 reference

23 July 2017

28

1 reference

23 July 2017

1

1 reference

23 July 2017

182-192

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300023

23 July 2017

0 references

cites work

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

Combined treatment of schizophrenic psychoses with haloperidol and valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

The Interaction Between GABA and Dopamine: Implications for Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

Valproate enhances inhibitory postsynaptic potentials in hippocampal neurons in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

Dopamine receptors and the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

Critical review of GABA-ergic drugs in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

7 January 2021

Augmentation of risperidone with valproic acid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

7 January 2021

Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

7 January 2021

Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

7 January 2021

Total cholesterol, high-density lipoprotein cholesterol, and triglycerides in children receiving antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

7 January 2021

The effect of chronic anticonvulsant therapy on serum lipids and lipoproteins in epileptic children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

7 January 2021

Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

7 January 2021

Enhancement of peroxisomal beta-oxidation in the liver of rats and mice treated with valproic acid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

7 January 2021

Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

7 January 2021

Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300023

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1300023

1 reference

Dimensions Publication ID

23 July 2017

0 references

1 reference